Cardiac Safety London


View Program

To help to enrich and speed up your drug development programs, join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss the latest state of the art methods in early phase clinical research. The event will provide insight to enable better patient outcomes, efficiency, and cost-effectiveness in global drug development.

The 20th of May also is World Clinical Trials Day celebrating the anniversary of the first clinical trial by James Lind in 1747 into the causes of scurvy on board the HMS Salisbury. On this occasion, we will also showcase work from our Research Institute, our not-for-profit affiliate dedicated to academic research.

Programme

  • Updates on the CSRC white paper on cardiac safety assessments of anti-diabetic medicines
  • Waveform analysis and measurements of QT subintervals
  • Repolarization disturbances in type 1 long QT syndrome patients
  • Cardiac safety embedded in adaptive clinical trials
  • Sex differences in cardiac risk
  • Regulatory updates in drug development
  • Preclinical science and models in cardiac safety assessments
  • Modelling and statistics of pharmacodynamic markers

Click here to view the agenda

This is an online event, to express an interest in this event or to learn more details please contact Jack Wilmott on j.wilmott@richmondpharmacology.com

Testimonials

“I am very pleased with the Project Management of both studies undertaken on behalf of (blank) and any future studies we have to outsource will automatically be contracted to you.”

- Anonymous

“Many thanks for your time today, most impressed with the quality of the follow up to our enquiry.”

- Anonymous

“Please know that it has been an absolute pleasure collaborating with you and that I am most appreciative of the key contributions RPL has made to this project thus far. I hope I have the opportunity to work with RPL again in the very near future.”

- Anonymous

Latest news

COVID-19 – External Monitoring Guidelines

04th May 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing

Read more ›

Statement on COVID-19

23rd Mar 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are

Read more ›

First transdermal patch to treat schizophrenia hits market

18th Mar 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia

Read more ›

Cardiac Safety London

Wednesday 20th May 2020 - 10am – 3.30pm BST

To help to enrich and speed up your drug development programs, join us for a day of discovery as global experts in

View event ›